Hypothesis

Aging is an actively maintained, programmed trait that limits individual lifespan to accelerate generational turnover and thereby increase inclusive fitness when relatedness exceeds a low threshold.

Mechanistic Basis

We propose that a conserved endocrine signal, termed generational factor (GF), is secreted by gonadal tissue after a reproductive threshold is reached. GF circulates systemically and activates the TGF‑β/SMAD pathway in somatic cells, driving a senescence program characterized by p16^INK4a^ upregulation and mitochondrial depolarization 2. In kin‑structured populations, GF‑induced death frees resources for relatives, boosting their reproductive output. The pathway is antagonized by nutrient‑sensing kinases (e.g., mTORC1) that are downregulated under caloric restriction, explaining why dietary restriction extends lifespan without altering the core program 3.

Testable Predictions

1. GF levels rise with age – measuring circulating GF in model organisms (e.g., Drosophila, mice) will show a sharp increase coinciding with the onset of senescence, and genetic ablation of GF‑producing cells will extend lifespan without affecting early‑life fertility 1.
2. GF signaling is necessary for age‑related senescence – loss‑of‑function mutants for the GF receptor will display delayed p16^INK4a^ activation and improved tissue homeostasis despite exposure to DNA damage.
3. Kin‑dependent fitness benefit – in structured populations where individuals are genetically related (e.g., viscous microbial colonies or mouse demes), overexpression of GF will increase the reproductive success of neighboring kin at the cost of the donor’s lifespan, whereas in well‑mixed populations GF overexpression will be selected against 4.
4. Reversibility – transient inhibition of GF signaling in aged animals will reversibly reduce senescence markers and restore regenerative capacity, indicating that the program is actively maintained rather than resulting from irreversible damage.

Experimental Approach

• Use CRISPR to tag and ablate GF‑secreting cells in zebrafish and monitor lifespan, fecundity, and age‑related pathology.
• Apply recombinant GF to young animals and assess senescence markers via immunostaining for p21 and SA‑β‑gal.
• Conduct competition experiments in spatially structured microbial ecosystems (e.g., Pseudomonas biofilms) with engineered GF producers vs. non‑producers, measuring colony growth and lineage survival over multiple generations.
• Administer GF‑neutralizing antibodies to aged mice and evaluate changes in frailty index, treadmill endurance, and transcriptome of senescence pathways.

If these predictions hold, aging would be viewed as a tunable, population‑level adaptation rather than an inevitable breakdown, reframing longevity medicine as a negotiation with an evolved life‑history strategy rather than a battle against random damage.